| |
Learn de-risking strategies in our whitepaper and explore the future of precision treatments from our survey of 100+ oncology professionals. 
|
|
Today’s Big NewsOct 16, 2024 |
|
Gene and cellular therapies hold the extraordinary potential to transform
global health care. Download the QPS White Paper to explore the 5 critical
criteria to consider when choosing the best CRO for your next cell and gene
therapy development program. ..png)
|
|
| By Kevin Dunleavy With GSK girding for competition from Gilead Sciences, the company has presented strong results from three real-world studies of its bi-monthly injection for HIV prevention. |
|
|
|
By James Waldron A phase 2 combination COVID-flu vaccine trial wrapped up in July 2023, with the “spontaneous” report of a patient developing motor neuropathy received last month. |
By Conor Hale With its seizure-spotting brain monitor, Ceribell rang in a $180.3 million IPO last week and saw its stock price trade up about 47% after the launch. |
By Nick Paul Taylor Takeda has brandished a termination notice at Wave Life Sciences, walking away from the last target in a collaboration that it has sunk $260 million into over the past six years. The decision leaves Wave holding a Huntington’s disease program that it says has caught the attention of other drug developers. |
|
Wednesday, October 23, 2024 | 11am ET / 8am PT Large, deeply characterized patient cohorts are one of the most promising data resources today for understanding disease biology and developing new medicines. Join us as we explore how this data is driving the next generation of pharmaceutical development. Learn how to leverage genetic research in today's highly competitive landscape. Register now. 
|
|
By Nick Paul Taylor Wave Life Sciences has taken a step toward validating a new modality, becoming the first group to report therapeutic RNA editing in humans. The update on the GSK-partnered prospect sent Wave’s share price up 63% to almost $14 despite coinciding with news that Takeda has axed a deal for another asset. |
By Nick Paul Taylor Boston Scientific has launched a docuseries campaign to remove the stigma of male incontinence. Across the videos, the campaign tells the stories of how incontinence upended the lives of three men—and how getting treated radically and rapidly improved their conditions. |
By Fraiser Kansteiner French unions have urged Sanofi employees to strike from the start of their shifts Thursday in a move covering “the whole of France." The industrial action hinges on concerns over job cuts and drug shortages tied to Sanofi's potential consumer health stake sale. |
By Conor Hale Novocure described its Tumor Treating Fields therapy as the first of its kind for the aggressive cancer, with its portable Optune Lua device placing wearable arrays on the chest or back. |
By Fraiser Kansteiner GSK is targeting Moderna in a pair of lawsuits claiming the mRNA specialist violated multiple patents with its vaccines Spikevax and mRESVIA. In the complaints, GSK says it hopes to recover a “reasonable royalty” tied to Moderna’s vaccine sales, plus damages. |
By Zoey Becker Eli Lilly is expanding its innovation digs to Beijing, opening two research centers called the Eli Lilly China Medical Innovation Center and Lilly Gateway Labs. |
By Angus Liu A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively pushing the earliest generic entry out to 2030. |
By Gabrielle Masson Big Pharma Sanofi is putting down $18 million across three historically Black medical schools in efforts of boosting clinical trial diversity. |
By Conor Hale NYU Langone Health has tapped Philips to help translate its glass tissue slides into high-def images and use AI to aid in diagnosis. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce Pharma's Fraiser Kansteiner chats with industry leaders about the surge in neuroscience investment, breakthroughs and future targets in neuropharmaceuticals. |
|
|---|
|
|
|
Thursday, October 24, 2024 | 1pm ET / 10am PT We will explore how incorporating comprehensive genetic services, like genetic testing access programs and clinical trial matching services, can increase identification of patients who meet program-specific inclusion/exclusion criteria, helping more patients benefit from life-changing therapeutics. Register today! 
|
|
eBook Need the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
Whitepaper Take a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
Whitepaper Unlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
